Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
The following is a guest post By Sharon Weir, Ph.D. of MEASURE Evaluation For almost 35 years, HIV/AIDS has been a household word across the globe. […]
New York – Every aspect of getting diagnosed and treated for tuberculosis violated rights established by the United Nations Universal Declaration of Human Rights, a former […]
A trial to test the safety of, and immune response prompted by, the latest candidate for a vaccine to protect against Zika virus infection has begun […]